Pharmacokinetics and pharmacodynamics of newer fluoroquinolones in patients with lower respiratory tract infections Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Population pharmacokinetics and pharmacodynamics analysis of vancomycin in patients with severe lower respiratory tract gram-positive infections Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Efficacy and safety of Cefdinir in lower respiratory tract infections Source: Eur Respir J 2002; 20: Suppl. 38, 420s Year: 2002
Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=229 Year: 2004
Treatment of respiratory tract infections: comparison of telithromycin and azithromycin Source: Eur Respir J 2004; 24: Suppl. 48, 638s Year: 2004
Pharmacokinetics of consecutive oral moxifloxacin 400 mg/day in patients with respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Immunomodulatory effects of moxifloxacin in human respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients Source: Eur Respir J, 53 (4) 1802107; 10.1183/13993003.02107-2018 Year: 2019
Respiratory tract infections and antibiotic resistance in a sample of Greek population Source: Eur Respir J 2003; 22: Suppl. 45, 486s Year: 2003
Telithromycin is as effective as comparator antibacterials in the treatment of lower respiratory tract infections Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? Source: Eur Respir J, 54 (5) 1901508; 10.1183/13993003.01508-2019 Year: 2019
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics? Source: Eur Respir J, 54 (5) 1901806; 10.1183/13993003.01806-2019 Year: 2019
High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult patients with respiratory tract infections Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
Safety, pharmacokinetics and pharmacodynamics of BI 1323495 in healthy males Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020
Clinical and demographic characteristics of lower respiratory tract infections in hospitalized children Source: Eur Respir J 2004; 24: Suppl. 48, 391s Year: 2004
Pharmacokinetic and pharmacodynamic issues in respiratory infections Source: Annual Congress 2013 –PG9 How to optimise antibiotic use in respiratory infections Year: 2013
Bacterial agents of community-acquired lower respiratory tract infections: observational study on antimicrobial drugs susceptibility Source: Eur Respir J 2002; 20: Suppl. 38, 421s Year: 2002
Telithromycin is highly efficacious in the treatment of lower respiratory tract infections Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
Influence of antibiotic resistance of pseudomonas aeruginosa on presenting features of community-acquired lower respiratory tract infections Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011
Clinical profile and risk factors in hospitalized children with lower respiratory tract infections Source: Eur Respir J 2007; 30: Suppl. 51, 392s Year: 2007